Abstract Details

Title Relationships Between Brain Volume and Disability, Cognition, Motor Function, and MS-Fatigue in Relapsing Multiple Sclerosis: MS-Fatigue and Ambulation Move at Their Own Pace

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 292

Objective We examined disability, cognition, motor function, and multiple sclerosis (MS)-fatigue related to the baseline and change in BV in the OPTIMUM study.

Background Brain Volume (BV) has been inconsistently related to symptoms and function in relapsing multiple sclerosis (RMS) trials.

Design/Methods Patients received ponesimod (20mg) or teriflunomide (14mg) over 108 weeks. Relationships were investigated across combined arms (n=1089). Normalized BV was determined at baseline and as Percentage Brain Volume Change (PBVC) at Week 60 (W60) and W108. Clinical assessments were Expanded disability status scale (EDSS); Multiple Sclerosis Functional Composite (MSFC); Timed 25-Foot Walk (T25FW); 9-Hole Peg Test (9- HPT); Paced Auditory Serial Addition Test (PASAT-3). Cognition was measured with the Symbol Digit Modalities Test score (SDMT) and MS-fatigue with the Fatigue Symptoms and Impact Questionnaire -RMS (FSIQ-RMS).

Results Correlations were statistically significant between baseline BV and all clinical measures at baseline (r range=-0.186 [T25FW] to 0.354 [MSFC], all p<0.001), W60 (r range = -0.150 [T25FW] to 0.321 [MSFC], all p<0.001), and W108 (r range=-0.176 [FSIQ-RMS] to 0.354 [MSFC], all p<0.001). Correlations were consistently higher between BV and MSFC and varied between changes in other clinical measures and PBVC at W60 and W108. At W60 and W108, PBVC remained significantly correlated to MSFC r=0.147 (p<0.001) and r=0.166 (p<0.001), EDSS r=-0.114 (p=0.001) and r=-0.195 (p<0.001), SDMT r=0.150 (p<0.001) and r=0.168, p<0.001), and 9-HPT r=-0.105 (p=0.003) and r=-0.197 (p<0.001). Correlation with T25FW was significant at W60 r= -0.102 (p=0.004) but not W108 r=-0.049 (p=0.190). Correlation with PASAT-3 was not significant at W60 r=0.065 (p=0.066) but was at W108 PASAT-3 r=0.100 (p<0.01). No correlation was found for FSIQ-RMS, W60 r=-0.002 (p=0.959) and W108 r=0.033 (p=0.428).

Conclusions There are statistically significant relationships between BV and clinical outcome measures of disability, cognition, motor function, and MS-fatigue; however, ambulation and MS-fatigue were not associated with the PBVC.

Authors/Disclosures
Frederik Barkhof, MD, PhD (Image Analysis Center) PRESENTER	Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Frederik Barkhof has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Combinostics. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IXICO. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI.
Maximilian Schuier, MD (Janssen)	Dr. Schuier has received personal compensation for serving as an employee of Janssen. Dr. Schuier has received stock or an ownership interest from Johnson & Johnson.
Ibrahim Turkoz (Janssen R&D)	Ibrahim Turkoz has received personal compensation for serving as an employee of Johnson and Johnson. Ibrahim Turkoz has stock in Johnson and Johnson.
David J. Williamson, PhD	Dr. Williamson has received personal compensation for serving as an employee of Janssen Scientific Affairs, LLC. Dr. Williamson has received stock or an ownership interest from Johnson & Johnson.
Alexander Keenan	Alexander Keenan has received personal compensation for serving as an employee of Janssen Pharmaceuticals. Alexander Keenan has received stock or an ownership interest from Johnson and Johnson.
Maria Ait Tihyaty (Johnson and Johnson Innovative Medicine)	Dr. Ait Tihyaty has received personal compensation for serving as an employee of Dianthus Therapeutics.

��ɫ��

��ɫ��